Plain-English translation of NCT07571161 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Alzheimer Disease research guide →Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
This study is testing a medication called to see if it can help prevent memory loss and cognitive decline in people who have early signs of Alzheimer's disease in their brain but are still thinking clearly. About half of participants will receive the new medication as an intravenous infusion (through a vein in the arm), while the other half will receive a placebo (inactive treatment). The goal is to understand whether this treatment can help protect thinking and memory skills over time.
Alzheimer's disease typically develops silently in the brain years before people notice memory problems. This medication may work by clearing harmful proteins from the brain before symptoms appear. This trial aims to discover whether treating people early, before cognitive decline begins, could prevent or slow Alzheimer's disease.
You likely qualify if…
You likely don't qualify if…
You would visit a research clinic approximately every few weeks for about three years. At each visit, you'll receive either the study medication or placebo as an intravenous infusion, undergo memory and thinking tests, have blood work drawn, and possibly have brain MRI scans. Your study partner will help track your daily functioning and cognitive abilities throughout the trial. The total time commitment involves regular clinic visits spaced over the 156-week study period.
AI-generated summary from trial data · Jul 13, 2026 · Not medical advice
China